Prognostic Value of Serum Interleukin-37 in Patients with Acute Respiratory Distress Syndrome.

BACKGROUND

Acute respiratory distress syndrome (ARDS) is prominently characterized by uncontrolled inflammation and high mortality. The effect of interleukin-37 (IL-37) on the prognosis of ARDS remains unclear.

METHODS

This prospective cohort study detected and analyzed serum IL-37 levels on day 1 (baseline) in 128 patients with ARDS and 40 healthy controls, and on day 7 in patients with ARDS. Clinical and laboratory parameters were assayed. Survival status was tracked within 28-d of enrollment.

RESULTS

BaselineIL-37 concentration was lower in non-survivors (135.00 [87.75, 198.75] pg/mL) than in survivors (250.50 [173.25, 382.75] pg/mL) (p < .05). Non-survivors displayed a greater reduction in IL-37 levels from day 1-7 than survivors (49.87% vs. 40.09%) (p < .05). Baseline IL-37 levels were negatively associated with C-reactive protein, procalcitonin, and IL-6 levels. The area under the receiver operating characteristic curve of the baseline level and percentage decline in IL-37 was 0.755 and 0.809, respectively, for predicting 28-d mortality. Combining IL-37 with the acute physiology and chronic health evaluation II score further improved mortality prediction capability. Patients with ARDS with low IL-37 concentrations (<143.00 pg/mL) or a high percentage decline (≥44.76%) had a poorer survival rate than those with a high concentration or low percentage decline. The baseline IL-37 level and percentage decline independently predicted mortality in a univariate Cox regression model (p < .05).

CONCLUSIONS

A low IL-37 level or significantly declining rate predicts higher 28-d mortality in patients with ARDS, indicating that IL-37 may be a promising prognostic biomarker.